NICE guidance on dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma

被引：1
作者：
Tucker, Helen [1 ]
Umeweni, Nwamaka [1 ]
Robertson, Janet [1 ]
Adam, Jane [1 ]
机构：
[1] Natl Inst Hlth & Care Excellence, London SW1A 2BU, England
来源：
LANCET ONCOLOGY | 2014年 / 15卷 / 13期
关键词：
OPEN-LABEL; PHASE-3;
D O I：
10.1016/S1470-2045(14)71033-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1425 / 1426
页数：2
相关论文
共 50 条
  • [1] Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective
    Fleeman, Nigel
    Bagust, Adrian
    Beale, Sophie
    Boland, Angela
    Dickson, Rumona
    Dwan, Kerry
    Richardson, Marty
    Dundar, Yenal
    Davis, Helen
    Banks, Lindsay
    PHARMACOECONOMICS, 2015, 33 (09) : 893 - 904
  • [2] Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Houten, Rachel
    Greenhalgh, Janette
    Mahon, James
    Nevitt, Sarah
    Beale, Sophie
    Boland, Angela
    Lambe, Tosin
    Dundar, Yenal
    Kotas, Eleanor
    McEntee, Joanne
    PHARMACOECONOMICS-OPEN, 2021, 5 (01) : 13 - 22
  • [3] Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China
    Gao, Tianfu
    Liu, Jia
    Wu, Jing
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (12)
  • [4] Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF V600 Mutation
    Dhillon, Sohita
    TARGETED ONCOLOGY, 2016, 11 (03) : 417 - 428
  • [5] Real-world efficacy and safety data for dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced melanoma
    Takahashi, Akira
    Namikawa, Kenjiro
    Nakano, Eiji
    Yamazaki, Naoya
    JOURNAL OF DERMATOLOGY, 2020, 47 (03) : 257 - 264
  • [6] Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study
    Fujiwara, Yutaka
    Yamazaki, Naoya
    Kiyohara, Yoshio
    Yoshikawa, Shusuke
    Yamamoto, Noboru
    Tsutsumida, Arata
    Nokihara, Hiroshi
    Namikawa, Kenjiro
    Mukaiyama, Akihira
    Zhang, Fanghong
    Tamura, Tomohide
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (02) : 259 - 268
  • [7] Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation-Positive Melanoma: Patient Selection and Perspectives
    Dugan, Michelle M.
    Perez, Matthew C.
    Karapetyan, Lilit
    Zager, Jonathan S.
    CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 933 - 939
  • [8] Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma
    Yamazaki, Naoya
    Tsutsumida, Arata
    Takahashi, Akira
    Namikawa, Kenjiro
    Yoshikawa, Shusuke
    Fujiwara, Yutaka
    Kondo, Shunsuke
    Mukaiyama, Akihira
    Zhang, Fanghong
    Kiyohara, Yoshio
    JOURNAL OF DERMATOLOGY, 2018, 45 (04) : 397 - 407
  • [9] A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors
    Kieran, Mark W.
    Geoerger, Birgit
    Dunkel, Ira J.
    Broniscer, Alberto
    Hargrave, Darren
    Hingorani, Pooja
    Aerts, Isabelle
    Bertozzi, Anne-Isabelle
    Cohen, Kenneth J.
    Hummel, Trent R.
    Shen, Violet
    Bouffet, Eric
    Pratilas, Christine A.
    Pearson, Andrew D. J.
    Tseng, Lillian
    Nebot, Noelia
    Green, Steven
    Russo, Mark W.
    Whitlock, James A.
    CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7294 - 7302
  • [10] Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL)
    Gonzalez-Barrallo, Ines
    Castellon Rubio, Victoria Eugenia
    Medina, Javier
    Espana, Sofia
    Mujika, Karmele
    Majem, Margarita
    Aguado, Carlos
    Cabrera Suarez, Miguel Angel
    Palacio, Isabel
    Osterloh, Lisa
    Martinez-Fernandez, Alejandro
    Garcia-Castano, Almudena
    MELANOMA RESEARCH, 2022, 32 (05) : 343 - 352
12345